These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20846829)

  • 1. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vitro activity of teicoplanin against gram-positive anaerobic bacteria.
    Anzivino D; Nani E; Gulletta E; Lembo M; Covelli B
    J Chemother; 1989 Jul; 1(4 Suppl):201-2. PubMed ID: 16312368
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.
    Ravizzola G; Pirali F; Foresti I; Turano A
    Drugs Exp Clin Res; 1987; 13(4):225-9. PubMed ID: 2957187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
    Mendes RE; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin microbiologic features and activity results from the surveillance program in the United States.
    Mendes RE; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S203-13. PubMed ID: 22431850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria].
    Caillon J; Juvin ME; Pirault JL; Drugeon HB
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):540-8. PubMed ID: 2552378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of daptomycin, vancomycin, teicoplanin and linezolid against resistant Gram-positive bacterial isolates from two large centres in western India.
    Biswas S; Watwani J; Vadwai V; Shetty A; Kelkar R; Rodrigues C
    Int J Antimicrob Agents; 2012 Dec; 40(6):567-9. PubMed ID: 22947124
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).
    Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
    J Antimicrob Chemother; 2016 Jan; 71(1):276-8. PubMed ID: 26451012
    [No Abstract]   [Full Text] [Related]  

  • 20. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
    Goldstein BP; Jones RN; Fritsche TR; Biedenbach DJ
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.